Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Jan 30, 2015
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • histologically verified squamous cell carcinoma of the head and neck region stage III and IV eligible for primary radiochemotherapy
- • measurabel disease by CT and/or MRT and/or FDG-PET-CT
- • fit for chemotherapy
- • no prior radiotherapy or major surgery in the head/neck region
- • Karnofsky Index \> 60%
- • informed consent
- Exclusion Criteria:
- • uncontrolled secondary cancer
- • distant metastases
- • pregnancy
- • expected malcompliance
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tuebingen, Baden Württemberg, Germany
Patients applied
Trial Officials
Stefan Welz, Dr. med.
Principal Investigator
radiation oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials